AQST Stock Risk & Deep Value Analysis

Aquestive Therapeutics, Inc.

DVR Score

7.2

out of 10

Solid Pick

The Bottom Line on AQST

We analyzed Aquestive Therapeutics, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran AQST through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Sep 7, 2025•Run Fresh Analysis →

📈AQST Performance Overview3yr weekly

📊

Unlock AQST Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

AQST Deep Value Analysis

Aquestive presents significant 10x growth potential, largely centered on Anaphylm™, a differentiated epinephrine film targeting a multi-billion-dollar market. Their proprietary PharmFilm® technology offers a strong competitive moat. Leadership has shown adaptability in navigating regulatory hurdles. A positive FDA approval for Anaphylm™ (PDUFA H2 2024) is a massive, near-term catalyst that could de-risk the company and unlock substantial market share. However, the company faces considerable regulatory, commercialization, and financial risks. Its path to profitability is heavily reliant on Anaphylm's success. Despite recent financing, the cash runway remains tight, and a growing debt burden coupled with high burn rate makes it a highly speculative, high-risk, high-reward opportunity rather than a 'dud.'

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

🔔

Never miss a move on AQST

Create a free account to set price alerts and get notified on Telegram when AQST hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Aquestive Therapeutics, Inc. (AQST)?

As of September 7, 2025, Aquestive Therapeutics, Inc. has a DVR Score of 7.2 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

How often is the AQST DVR analysis updated?

Our AI-powered analysis of Aquestive Therapeutics, Inc. is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on September 7, 2025.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.